Dr Sara Howden
Dr Sara Howden
Details
Role
Scientific Lead
Group
iPSC Derivation & Gene Editing Facility
Dr Sara Howden leads the Murdoch Children’s Research Institute iPSC Derivation and Gene Editing Facility, which is supported by the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) and Phenomics Australia.
Dr Sara Howden is an expert in human reprogramming and genome engineering technologies. During her tenure as a National Health and Medical Research Council postdoctoral fellow at the University of Wisconsin, she worked with Professor James Thomson to develop enhanced reprogramming and genome engineering technologies. She was first to report targeted gene repair in patient-specific induced pluripotent stem cells (iPSCs).
Dr Howden has developed Cas9 variants for improve gene-editing outcomes and streamlined protocols for the swift and efficient production of gene-edited iPSCs from human skin or blood. These techniques have been widely adopted by researchers in the global stem cell research community and are routinely used at the MCRI iPSC Derivation and Gene Editing Facility, which Dr Howden founded in 2017. This facility has produced hundreds of custom-edited iPSC lines for researchers both locally and internationally.
Dr Howden is leading a team that are actively engaged in supporting the next generation of stem cell researchers by providing hands-on training to individuals or small groups onsite within the facility.
Dr Sara Howden is an expert in human reprogramming and genome engineering technologies. During her tenure as a National Health and Medical Research Council postdoctoral fellow at the University of Wisconsin, she worked with Professor James Thomson to develop enhanced reprogramming and genome engineering technologies. She was first to report targeted gene repair in patient-specific induced pluripotent stem cells (iPSCs).
Dr Howden has developed Cas9 variants for improve gene-editing outcomes and streamlined protocols for the swift and efficient production of gene-edited iPSCs from human skin or blood. These techniques have been widely adopted by researchers in the global stem cell research community and are routinely used at the MCRI iPSC Derivation and Gene Editing Facility, which Dr Howden founded in 2017. This facility has produced hundreds of custom-edited iPSC lines for researchers both locally and internationally.
Dr Howden is leading a team that are actively engaged in supporting the next generation of stem cell researchers by providing hands-on training to individuals or small groups onsite within the facility.
Dr Sara Howden leads the Murdoch Children’s Research Institute iPSC Derivation and Gene Editing Facility, which is supported by the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) and Phenomics Australia.
Dr Sara Howden is an expert...
Dr Sara Howden is an expert...
Dr Sara Howden leads the Murdoch Children’s Research Institute iPSC Derivation and Gene Editing Facility, which is supported by the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) and Phenomics Australia.
Dr Sara Howden is an expert in human reprogramming and genome engineering technologies. During her tenure as a National Health and Medical Research Council postdoctoral fellow at the University of Wisconsin, she worked with Professor James Thomson to develop enhanced reprogramming and genome engineering technologies. She was first to report targeted gene repair in patient-specific induced pluripotent stem cells (iPSCs).
Dr Howden has developed Cas9 variants for improve gene-editing outcomes and streamlined protocols for the swift and efficient production of gene-edited iPSCs from human skin or blood. These techniques have been widely adopted by researchers in the global stem cell research community and are routinely used at the MCRI iPSC Derivation and Gene Editing Facility, which Dr Howden founded in 2017. This facility has produced hundreds of custom-edited iPSC lines for researchers both locally and internationally.
Dr Howden is leading a team that are actively engaged in supporting the next generation of stem cell researchers by providing hands-on training to individuals or small groups onsite within the facility.
Dr Sara Howden is an expert in human reprogramming and genome engineering technologies. During her tenure as a National Health and Medical Research Council postdoctoral fellow at the University of Wisconsin, she worked with Professor James Thomson to develop enhanced reprogramming and genome engineering technologies. She was first to report targeted gene repair in patient-specific induced pluripotent stem cells (iPSCs).
Dr Howden has developed Cas9 variants for improve gene-editing outcomes and streamlined protocols for the swift and efficient production of gene-edited iPSCs from human skin or blood. These techniques have been widely adopted by researchers in the global stem cell research community and are routinely used at the MCRI iPSC Derivation and Gene Editing Facility, which Dr Howden founded in 2017. This facility has produced hundreds of custom-edited iPSC lines for researchers both locally and internationally.
Dr Howden is leading a team that are actively engaged in supporting the next generation of stem cell researchers by providing hands-on training to individuals or small groups onsite within the facility.
Top Publications
- Higgins, JW, Chambon, A, Bishard, K, Hartung, A, Arndt, D, Brugnano, J, Er, PX, Lawlor, KT, Vanslambrouck, JM, Wilson, S, et al. Bioprinted pluripotent stem cell-derived kidney organoids provide opportunities for high content screening. 2026 view publication
- Howden, SE, Vanslambrouck, JM, Wilson, SB, Tan, KS, Little, MH. Fate-mapping within human kidney organoids reveals conserved mammalian nephron progenitor lineage relationships. 2026 view publication
- Wilson, SB, Howden, SE, Vanslambrouck, JM, Dorison, A, Alquicira-Hernandez, J, Powell, JE, Little, MH. DevKidCC allows for robust classification and direct comparisons of kidney organoid datasets. 2026 view publication
- Pocock, M, Reid, JD, Robinson, HR, Charitakis, N, Krycer, JR, Foster, SR, Fitzsimmons, RL, Lor, M, Tuano, N, Howden, S, et al. Maturation of human cardiac organoids enables complex disease modelling and drug discovery. 2026 view publication
- Suter, A, Graham, A, Kuah, JY, Crisologo, J, Gunatilake, C, Sourris, K, See, M, Rossello, FJ, Ramialison, M, Vlahos, K, et al. Efficient installation of heterozygous mutations in human pluripotent stem cells using prime editing. 2026 view publication
Page 1 of 14
Career information
Share //
